Navigation Links
Study Published in Nature Biotechnology Demonstrates Ability of Moderna's Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
Date:9/8/2013

Chien. "Over the past 20 years, many labs have attempted to repair damaged heart muscle in animal models by delivering VEGF-A and other factors to the heart using recombinant proteins, DNA plasmids, and engineered viruses—with little if any clinical success. The results we have seen using messenger RNA therapeutics™ mark the start of a new and exciting phase of drug development with potentially profound implications for patients."

In the study, the mice injected with VEGF-A-coded messenger RNA produced a "pulse-like" expression of a significant quantity of VEGF-A near the injection site. The production of VEGF-A in turn mobilized heart progenitor cells to produce functional, intact blood vessels in the heart and led to marked improvements in heart function and improved long-term survival of the mice for at least one year post-MI. Researchers attribute these effects to a reduction in the size of infarct region and an increase in capillary density in the affected region. In this way, the high-level, transient production of VEGF-A led to a sustained therapeutic improvement by altering the behavior of heart progenitor cells. 

Introduction of modRNA was not associated with an innate immune response, further supporting the safety and effectiveness of this novel approach.

"We are extremely proud that our messenger RNA therapeutics™ platform enabled Ken to realize his vision and clinical intuition of the last 20 years," said Stephane Bancel, president and founding CEO of Moderna. "Beyond the considerable implications for the treatment of heart injury, this publication provides an important validation of the potential of messenger RNA therapeutics™ across a wide range of diseases. The ability to stimulate protein production within cells will enable the treatment of many diseases that cannot be addressed today. What is also exciting is the fact that the Moderna team has considerably improved our
'/>"/>

SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. iLab Solutions Announces the Results of the 2013 Core Facility Benchmarking Study
2. ResearchMoz.us: Private Healthcare Market - Investigation, Study, Size, Share in Central Europe and Poland and Poland 2013
3. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
4. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
5. Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
6. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
7. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
8. BioStorage Technologies Launches INTEGRITY Study to Measure Effect of Time, Temperature and Preparation Methods on DNA and RNA Samples
9. Study Scavenger and CenterWatch Partner to Improve Patient Recruitment, Enrollment and Mobile Access to Clinical Trials with New Study Scavenger Smartphone App
10. VG Energy Chief Scientist Awarded $200,000 AgriLife Grant to Study Lipid Secretion
11. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Seattle, WA (PRWEB) July 29, 2014 ... central IRB services, has been awarded accreditation by ... (IASSC) for its Lean Six Sigma Deployment ... eliminate waste and improve performance. , Quorum’s Lean ... granted the Accredited Deployment Program designation. The designation ...
(Date:7/29/2014)... CA (PRWEB) July 29, 2014 ... Pipette.com’s centrifugation product selection. Eppendorf 5427 R is geared ... and DNA – it is targeted towards work requiring ... Centrifuge 5427 R as it compliments their extensive 16, ... Eppendorf line of microcentrifuge tubes, PCR tubes, PCR strip ...
(Date:7/29/2014)... EXpressLO LLC, expert provider of focused ... solutions, has been granted patent number 8,789,826 by the ... incorporating a unique specimen carrier support grid design described ... company patent for EXpressLO LLC awarded to founder and ... complementary patents extend EXpressLO’s portfolio of intellectual property. The ...
(Date:7/28/2014)... July 28, 2014 The Workgroup for ... on the use of health IT to create efficiencies ... Plan Identifier (HPID) Workgroup has developed an issue ... Plan and Payer?” The HPID Workgroup, a part of ... the Centers for Medicare and Medicaid Services (CMS) to ...
Breaking Biology Technology:Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2
... VANCOUVER, Sept. 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... today that it received a,favourable decision from ... an attempt by Johnson & Johnson,s subsidiary, ... Zealand Patent 523799, which,pertains to compositions comprising ...
... ROCKVILLE, Md., Sept. 12 BioReliance Corporation, ... and,pharmaceutical industries, has contracted with Gentronix to ... a major part of BioReliance,s portfolio of,genotoxicity ... Ames,II assays, allows pharmaceutical companies to test ...
... 2007 Medical Products Industry Leader, DEERFIELD, Ill., Sept. ... today that it has been named 2007,Medical Products Industry ... and the Dow Jones Sustainability North America Index,(DJSI North ... has been listed in the DJSI and the sixth ...
Cached Biology Technology:Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 2Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 3Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 4BioReliance Launches Next-Generation Genotoxicity Screening Service 2Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year 2
(Date:7/29/2014)... from scientists at the University of Kent has shown ... are regulated a breakthrough that could have a ... from Kent,s School of Biosciences uncovered the mechanism whereby ... known as actin filaments are ,fine-tuned, to ... filaments appear to completely stable, providing a framework for ...
(Date:7/29/2014)... a rare disease it affects 1 in 100,000 people ... esophageal wall. While its cause remains unknown, a new study ... the University of Bonn in Germany and other European institutions ... origin. The study, published on 6 July in Nature ... disease. , When we swallow, a sphincter in the lower ...
(Date:7/28/2014)... the South Pole in 1911, but new research shows ... , Using data from 16 ice cores collected from ... South Pole, a group led by Joe McConnell of ... the most accurate and precise reconstruction to date of ... described in an article published today in the online ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... the arteries weren't bad enough, a research team from the ... Newark has now confirmed that even our veins stiffen as ... are nice and elastic--like rubber bands," William Farquhar, a cardiovascular ... you grow older, we've found that your veins become more ...
... during periods of stress may increase the growth rate of ... that an increase in norepinephrine, a stress hormone, can stimulate ... down of the tissue around the tumor cells and allow ... there, they can travel to another location in the body ...
... first time, coaxed umbilical cord blood stem cells to differentiate into ... into a type of lung cell called type II alveolar cells. ... allows the air sacs in the lungs to remain open, allowing ... are also responsible for helping to repair the airway after injury. ...
Cached Biology News:Researchers show that veins stiffen as we age 2Researchers show that veins stiffen as we age 3Researchers show that veins stiffen as we age 4Stress hormones may play new role in speeding up cancer growth 2Stress hormones may play new role in speeding up cancer growth 3U of MN researchers turn cord blood into lung cells 2
... The SilverQuest Silver Staining Kit is ... staining sensitivity with minimal protein modification ... mass spectrometry problems associated with traditional ... SilverQuest kit because the reagents used ...
...
... Insect Medium is formuatled for the ... Sf9 and Sf21 cells. Grace's Insect ... because it does not contain lactalbumin ... with transfection. Grace's Insect Medium, Supplemented ...
Schneider's Drosophila Medium is formulated for the expression of heterologous proteins in Drosophila S2 cells....
Biology Products: